Core Points - Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. announced a cash dividend of 0.27 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on May 13, 2025 [2][3][4] - The total cash dividend distribution amounts to approximately 53.53 million yuan, based on a total share capital of 198,243,911 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Distribution Plan - The cash dividend distribution is based on the company's total share capital as of the record date, with each share receiving a cash dividend of 0.27 yuan (before tax) [4] - The distribution will be managed by the China Securities Depository and Clearing Corporation, with shareholders who have completed designated transactions able to receive their dividends on the payment date [6][8] Taxation Details - For individual shareholders holding unrestricted shares, no income tax will be withheld at the time of dividend distribution; tax will be calculated based on the holding period when shares are sold [9] - For shares held for less than one month, the tax rate is 20%; for one month to one year, the tax rate is 10%; and for over one year, dividends are exempt from personal income tax [9] - For foreign institutional investors, a 10% withholding tax will apply, resulting in a net dividend of 0.243 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds ("Shu 22 Convertible Bonds") due to the dividend distribution, changing from 37.11 yuan to 36.84 yuan per share [19][21] - The adjustment will take effect on June 6, 2025, with the bonds being suspended from conversion from May 28 to June 5, 2025 [21]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-040 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.27元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/5 | － | 2025/6/6 | 2025/6/6 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-041 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于权益分派引起的 "寿 22 转债"转股价格调整暨转股复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因实施 2024 年度权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 113660 | 寿 22 | 转债 | 可转债转股复牌 | | | 2025/6/5 | 2025/6/6 | 经中国证券监督管理委员会"证监许可[2022]2165 号"文核准，浙江寿仙谷医药 股份有限公司（以下简称"公司"、"寿仙谷"）于 2022 年 11 月 17 日公开发行 ...

Group 1 - The first National Investment Conference of Shouxiangu was held in Wuyi County, Zhejiang, focusing on the modernization of traditional Chinese medicine and the development of the health industry [1] - Shouxiangu is the first company in China to independently cultivate a new variety of Ganoderma, named "Xianzhi No. 1," and showcased its full-process quality control system from breeding to production [1] - The company announced a ten-year market expansion plan, utilizing a dual-channel model of "mainly specialty stores + traditional medicine lines," along with eight support measures to assist partners in market expansion [1] Group 2 - During the conference, Shouxiangu signed strategic cooperation agreements with seven partners from the pharmaceutical and health product sectors, indicating strong market potential and brand value [2] - The company aims to enhance its core competitiveness by deepening cooperation with distributors and maintaining its philosophy of "inheriting the thousand-year Ganoderma culture and empowering the health industry with technology" [2] - The chairman of the company expressed a grand vision of establishing a global benchmark for the Ganoderma industry [2]

Core Viewpoint - The article discusses the superiority of cultivated Ganoderma (Lingzhi) over wild varieties, emphasizing the importance of quality control in traditional Chinese medicine (TCM) and highlighting the achievements of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. in this field [2][3]. Group 1: Company Overview - Zhejiang Shouxiangu is a national high-tech enterprise and a time-honored brand that focuses on solving the challenges of high-quality raw materials and product transformation in rare Chinese medicinal materials [2]. - The company has developed a comprehensive quality control model that integrates germplasm resource protection, breeding, organic cultivation, traditional processing, and modern extraction techniques [2][3]. Group 2: Research and Development - Shouxiangu has established the world's largest Ganoderma germplasm resource bank, containing over 10,000 entries, including both wild and cultivated varieties through advanced breeding techniques [3]. - The company has created over ten excellent varieties through its breeding efforts and has established over 10,000 acres of ecological planting bases certified by multiple international and national organic product standards [3]. Group 3: Historical Background and Achievements - Founded in 1909, Shouxiangu has a long history of producing high-quality medicinal products, adhering to strict quality standards set by its founders [4]. - The company has undertaken over 100 national and provincial scientific projects, achieving significant technological advancements and receiving more than 40 awards for scientific progress [4]. Group 4: Future Strategy - Shouxiangu aims to leverage its technological innovations to enhance market competitiveness and is committed to building a comprehensive ecosystem covering research, production, sales, and services [5]. - The recent national招商大会 (investment promotion conference) marks the beginning of a rapid implementation phase for the company's strategic goals [5][6].

Core Viewpoint - Shouxiangu held its first national招商大会 in Wuyi, Zhejiang, showcasing its growth in the health industry and strategic layout under the theme "World's Best Ganoderma·China Shouxiangu" [1] Group 1: Company Achievements and Innovations - Shouxiangu is a key player in the full industry chain of rare medicinal materials such as Ganoderma and Dendrobium, from breeding to advanced production techniques, clinical research, and brand upgrading [3] - The company won the National Science and Technology Progress Award First Class for the project "Key Technology Innovation and Application of the Full Industry Chain of Edible and Medicinal Fungi" in 2024 [3] - The company aims to become a global benchmark in the Ganoderma industry, emphasizing data-driven results to support its transformation from "accumulation" to "explosion" [3] Group 2: Strategic Development and Market Expansion - Shouxiangu's new channel strategy focuses on a layout of "mainly specialty stores + traditional medicine channels" outside the province, with a tiered franchise system [4] - The company has implemented eight support measures to ensure rapid market expansion for commercial partners, promoting a "short profit + long value" retail ecosystem [4] - Seven strategic partners signed agreements with Shouxiangu at the招商大会, highlighting the company's commitment to enhancing core competitiveness through technology and deep cooperation with distributors [4]

Group 1 - The core theme of the first national招商大会 hosted by Zhejiang Shouxiangu Pharmaceutical Co., Ltd. is "World's Good Ganoderma, China's Shouxiangu," showcasing the company's achievements in the health industry and future strategic direction [2] - Shouxiangu has been deeply involved in the rare medicinal materials sector, particularly Ganoderma and Dendrobium, for 40 years, establishing a comprehensive industry chain that includes breeding, advanced production technology, clinical research, and brand upgrading [2] - The company is the first in China to independently cultivate a new variety of Ganoderma called "XianZhi No. 1" and is currently the only company globally that possesses the core technology for the wall-breaking of Ganoderma spore powder [2] Group 2 - Chairman Li Mingyan emphasized the vision of "building a global benchmark for the Ganoderma industry" and highlighted the company's transition from "accumulation" to "explosion" in growth [3] - The conference marked the rapid implementation of the strategy focusing on "technology-driven enterprise, strong management, and marketing-driven enterprise" [3] - Looking ahead, Shouxiangu aims to enhance its core competitiveness, strengthen deep cooperation with distributors, and build a closely coordinated network to jointly explore the market, targeting a new journey towards a "100 billion-level" enterprise [3]

Core Viewpoint - The legal opinion letter confirms that the actual controller of Zhejiang Shouxiangu Pharmaceutical Co., Ltd., Mr. Li Zhenyu, has legally increased his shareholding in the company, complying with relevant laws and regulations [3][12]. Group 1: Shareholding Increase Details - Mr. Li Zhenyu directly held 5,114,161 shares before the increase, accounting for 2.58% of the total share capital [8]. - After the increase, Mr. Li Zhenyu holds 9,078,961 shares, representing 4.58% of the total share capital [10]. - The total shareholding controlled by Mr. Li Zhenyu and his concerted actors reached 40.77% after the increase [10]. Group 2: Compliance and Legal Qualification - Mr. Li Zhenyu is confirmed to have full civil capacity and meets the qualifications to be a shareholder of a listed company, with no prohibitive conditions as per the regulations [8][12]. - The increase in shareholding was executed through the Shanghai Stock Exchange, totaling 3,964,800 shares, which is 2% of the total share capital, and the total amount spent was approximately RMB 82.0992 million [9][10]. - The increase complies with the provisions of the Securities Law and the M&A Regulations, and it qualifies for exemption from making a tender offer [12]. Group 3: Information Disclosure - The company has fulfilled its information disclosure obligations regarding the shareholding increase, as evidenced by announcements made on May 6 and May 13, 2025 [11]. - The legal opinion letter states that the company must continue to fulfill its disclosure obligations regarding the implementation of the shareholding increase plan [11].

| 证券代码：603896 证券简称：寿仙谷 | | | 公告编号：2025-039 | | | | | --- | --- | --- | --- | --- | --- | --- | | 债券代码：113660 债券简称：寿 22 转债 | | | | | | | | 浙江寿仙谷医药股份有限公司 | | | | | | | | 关于实际控制人之一、董事兼总经理增持股份结果公告 | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | 重要内容提示： | | | | | | | | ? 已披露增持计划情况：浙江寿仙谷医药股份有限公司（以下简称"寿仙 | | | | | | | | 谷"或"公司"）于 2025 年 5 月 6 日在上海证券交易所网站披露了《寿仙谷关于 | | | | | | | | 实际控制人之一、董事兼总经理增持股份计划及实施情况公告》（公告编号： | | | | | | | | 次增持不低于 2,000,000 股，不 ...

证券代码：603896 证券简称：寿仙谷 公告编号：2025-039 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于实际控制人之一、董事兼总经理增持股份结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：浙江寿仙谷医药股份有限公司（以下简称"寿仙 谷"或"公司"）于 2025 年 5 月 6 日在上海证券交易所网站披露了《寿仙谷关于 实际控制人之一、董事兼总经理增持股份计划及实施情况公告》（公告编号： 2025-027），公司实际控制人之一、董事兼总经理李振宇先生计划自 2025 年 4 月 30 日起 6 个月内，通过上海证券交易所以集中竞价交易方式增持公司股份；本 次增持不低于 2,000,000 股，不超过 3,964,877 股；本次增持不设价格区间。 （一）增持计划的实施结果 | 增持主体名称 | 李振宇 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | -- ...